MedPath

Renal Denervation in Patients After Acute Coronary Syndrome

Phase 2
Conditions
Acute Coronary Syndrome
Arterial Hypertension
Interventions
Procedure: Renal denervation
Registration Number
NCT01901549
Lead Sponsor
Meshalkin Research Institute of Pathology of Circulation
Brief Summary

This study is aimed to evaluate the effect of renal denervation to decreasing blood pressure and left ventricle remodeling progression in patients after acute coronary syndrome.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
80
Inclusion Criteria
  • acute Q negative myocardium infarction (during first 14 days)
  • non stable angina
  • significant stenosis
  • BP > 140/90 torr. during more than 1 year
Exclusion Criteria
  • absence of arterial hypertension
  • Thrombolysis during previous 24 hours
  • indications for CABG

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PCI+Renal denervationRenal denervation-
PCI+Renal denervationMetoprolol-
PCI aloneLisinopril-
PCI aloneMetoprolol-
PCI+Renal denervationLisinopril-
Primary Outcome Measures
NameTimeMethod
cardiovascular death1 year
myocardium infarction1 year
stroke1 year
repeat revascularization1 year
Secondary Outcome Measures
NameTimeMethod
blood pressure changes1 year
CCS and NYHA1 year
heart rhythm disturbances1 year
intima-media index1 year
IVS thickness1 year
restenosis1 year
diastolic disfunction1 year

Trial Locations

Locations (1)

State Research Institute of Circulation Pathology

🇷🇺

Novosibirsk, Russian Federation

State Research Institute of Circulation Pathology
🇷🇺Novosibirsk, Russian Federation
Evgeny Pokushalov, MD, PhD
Principal Investigator
Alexander Romanov, MD
Sub Investigator
Alexander Osiev, MD PhD
Sub Investigator
Igor Grazhdankin, MD
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.